Biosyent 

$10.01
30
+$0.01+0.1% Monday 19:39

Statistics

Day High
10.01
Day Low
10
52W High
12
52W Low
7.63
Volume
1,200
Avg. Volume
-
Mkt Cap
114.86M
P/E Ratio
17.8
Dividend Yield
1.59%
Dividend
0.16

Upcoming

Dividends

1.59%Dividend Yield
Jun 26
$0.04
Mar 26
$0.04
Dec 25
$0.04
Sep 25
$0.04
Jun 25
$0.04
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
10.91%
1Y Growth
12.66%

Earnings

25AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
0.1
0.12
0.14
0.17
Expected EPS
N/A
Actual EPS
N/A

Financials

20.78%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
49.79MRevenue
10.34MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BIOYF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap149.38B
Pfizer is a global pharmaceutical company that competes with Biosyent in the development and marketing of various pharmaceutical products, including those in Biosyent's portfolio.
Merck
MRK
Mkt Cap294.03B
Merck & Co., Inc. is a leading pharmaceutical company that offers products in similar therapeutic areas as Biosyent, making it a direct competitor.
Abbvie
ABBV
Mkt Cap402.35B
AbbVie competes with Biosyent in the pharmaceutical sector, particularly in areas like specialty pharmaceuticals where Biosyent operates.
Johnson & Johnson
JNJ
Mkt Cap579.83B
Johnson & Johnson, through its pharmaceutical division, competes across a broad range of therapeutic areas, overlapping with Biosyent's market.
GSK
GSK
Mkt Cap106.31B
GlaxoSmithKline is a global healthcare company that has a competitive presence in the pharmaceutical and healthcare market, similar to Biosyent.
Novo Nordisk
NVO
Mkt Cap194.35B
Novo Nordisk is a leading global healthcare company that competes with Biosyent in the pharmaceutical sector, particularly in treatments for diabetes and other conditions.
Sanofi
SNY
Mkt Cap105.92B
Sanofi is a multinational pharmaceutical company that competes with Biosyent in various therapeutic areas, including those targeted by Biosyent's products.
Astrazeneca
AZN
Mkt Cap277.22B
AstraZeneca is a global, science-led biopharmaceutical business that competes with Biosyent in developing and commercializing prescription medicines.
Bristol-Myers Squibb
BMY
Mkt Cap116.66B
Bristol Myers Squibb is a global biopharmaceutical company whose range of products and research areas overlap with those of Biosyent.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap40.32B
Teva Pharmaceutical Industries is a global leader in generic and specialty medicines, competing with Biosyent in both the generic and branded pharmaceutical markets.

About

BioSyent Inc., headquartered in Mississauga, Canada, is a specialized pharmaceutical firm that was established in 2006. The company, which changed its name from Hedley Technologies Inc. in June 2006 to underscore its focus on the pharmaceutical sector, operates internationally as well as within Canada. Its business model involves identifying, acquiring or licensing, developing, and ultimately commercializing various pharmaceutical and healthcare products. The company's diverse product portfolio features several key offerings. These include the FeraMAX line of iron supplements: FeraMAX 150, an oral hematinic; FeraMAX Powder, a water-soluble oral iron supplement designed to assist in red blood cell formation; and FeraMAX Pd Therapeutic 150, which is specifically formulated for the prevention and treatment of iron deficiency anemia. Additionally, BioSyent provides Cathejell, a product utilized for both surface anesthesia and lubrication during a variety of medical procedures, such as cystoscopy, catheterization, endourethral operations, endoscopy, proctoscopy, rectoscopy, and tracheal intubation. It also helps in alleviating pain associated with conditions like cystitis and urethritis. For women's health, RepaGyn is offered as a vaginal suppository to promote the healing of vaginal mucosa and address dryness caused by menopause, stress, or chemotherapy. Similarly, Proktis-M is a rectal suppository aimed at healing the anal and rectal areas. Other notable products encompass Combogesic, intended for adults seeking relief from moderate acute pain and fever reduction. Interestingly, BioSyent also distributes Protect-It, a non-chemical, food-safe grain insecticide used as a preventative measure against insect infestations in stored grains. Furthermore, Tibella is available as a hormone replacement therapy to manage vasomotor symptoms resulting from estrogen deficiency. BioSyent distributes its products through established channels, including wholesale partners and retail pharmacy chains.
Show more...
CEO
Mr. René C. Goehrum
Employees
60
Country
Canada
ISIN
CA0906901081

Listings

0 Comments

Share your thoughts

FAQ

What is Biosyent stock price today?
The current price of BIOYF is $10.01 USD — it has increased by +0.1% in the past 24 hours. Watch Biosyent stock price performance more closely on the chart.
What is Biosyent stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Biosyent stocks are traded under the ticker BIOYF.
Is Biosyent stock price growing?
BIOYF stock has risen by +1.93% compared to the previous week, the month change is a -4.67% fall, over the last year Biosyent has showed a +16.94% increase.
What is Biosyent market cap?
Today Biosyent has the market capitalization of 114.86M
When is the next Biosyent earnings date?
Biosyent is going to release the next earnings report on August 25, 2026.
What were Biosyent earnings last quarter?
BIOYF earnings for the last quarter are 0.14 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Biosyent revenue for the last year?
Biosyent revenue for the last year amounts to 49.79M USD.
What is Biosyent net income for the last year?
BIOYF net income for the last year is 10.34M USD.
Does Biosyent pay dividends?
Yes, BIOYF dividends are paid quarterly. The last dividend per share was 0.04 USD. As of today, Dividend Yield (FWD)% is 1.59%.
How many employees does Biosyent have?
As of June 16, 2026, the company has 60 employees.
In which sector is Biosyent located?
Biosyent operates in the Health & Wellness sector.
When did Biosyent complete a stock split?
Biosyent has not had any recent stock splits.
Where is Biosyent headquartered?
Biosyent is headquartered in Mississauga, Canada.